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ABSTRACTSwere independent with some or minimal discomfort. 14 patients required
assistance for some of their basic daily needs. 9 patients (2.2%) had sepsis.
131 patients (32.4%) required additional oral analgesia following TRUSBx
on days 0, 1 and 2. Mean age of these patients was 63.6 years. This group
had mean VAS during the procedure of 4 and when patients reached home
was 3.5. Mean maximum VAS on day 1 and 2 was 2.1 and 1.3 respectively.
Conclusion: A third of patients require self-medicated analgesia post-
procedure. Age alone cannot be used as a criterion to identify patients who
will subsequently require analgesia post-procedure, but a higher VAS
during the procedure may be indicative.
1304: CHAIRING AND LEADERSHIP IN MULTIDISCIPLINARY CANCER
TEAMS: DEVELOPMENT AND EVALUATION OF AN ASSESSMENT TOOL
Rozh Jalil 1, Waseem Akhter 2, James Green 2, Nick Sevdalis 1. 1 Imperial
College London, London, UK; 2Barts Health NHS Trust, London, UK.
Introduction: High quality leadership and chairing skills are vital for good
performance in cancer multidisciplinary teams(MDTs), but no tools exist
for assessment. Our objective was to construct a robust tool for assessment
of MDT-chairing performance.
Methods: An observational tool was developed to assess the chairing and
leadership skills of MDT chair. The tool includes 11 elements of effective
MDT chairing. After it was content-validated by 10 senior MDT members,
theMDTchair personwas assessed by two surgeons(blinded to each other)
in seven live-observed Urology MDT meetings (286 cases) and ten video
recorded MDTs(131 cases) of different specialities. All chairing elements
were analysed via descriptive statistics. Intraclass correlation coef-
ﬁcients(ICCs) were used to assess inter-rater agreement and assessors'
learning curves.
Results: The inter-rater agreement was adequate-high(ICC¼ 0.63-0.91) for
all of the chairing elements. Agreement was higher in live MDT rat-
ings(mean 0.79,SD 0.092) compared to video ratings(mean 0.72,SD 0.069).
Conclusion: an observational assessment tool can be reliably used for
assessing the chair person in cancer MDTs (both in live and video-recor-
ded). Such robust assessment tools provide part of a toolkit for MDT
leadership evaluation and enhancement. The ability to feed back their
performance to MDT leads can enable promotion of good practice.
1308: HYPERTHERMIC MITOMYCIN C IN THE TREATMENT OF HIGH RISK
NON MUSCLE INVASIVE BLADDER CANCER e IS IT EFFECTIVE AND
SAFE? A REGIONAL CENTRE'S EXPERIENCE
Tsong Kwong, Anand Tana, Ben Ayres, Matthew Perry, Mike Bailey,
Rami Issa. St George's Hospital, London, UK.
Aims: High risk non muscle invasive bladder cancer (HRNMIBC) is
commonly treated with intravesical BCG, but fails in approximately 50% of
patients after 5 years. Hyperthermic Mitomycin C (HTMMC) is now being
considered for patients who failed BCG and avoid cystectomy. Our pro-
spective study was to investigate efﬁcacy and tolerance of HTMMC and
factors that inﬂuence success.
Methods: Patients with HRNMIBC who failed BCG or are immunocom-
promised were treated with HTMMC from June 2006 to June 2012. In-
duction HTMMC was given at 42+/-2oC through a Synergo device, with
induction and regular maintenance courses. Every three months, cystos-
copy and cytology was taken.
Results: Of 95 eligible patients, 75 completed at least one review. 77% of
patients had a complete response with HTMMC. High grade cancer and CIS
did not inﬂuence HTMMC initial response. No Clavien score over 2 was
reported. Median follow up was 33 (3-78) months. At 5 years, disease
speciﬁc survival was 96.8%, overall survival was 82.3% and failure-free
survival was 47.6%. 14 proceeded to cystectomy on HTMMC failure, with 11
performed locally. Of the 11, all had organ-conﬁned disease.
Conclusion: HTMMC is well tolerated and suitable treatment for patients
who are unﬁt or do not wish cystectomy.
1317: THE USE OF STAGING AND MULTIPARAMETRIC MRI IN PROSTATE
CANCER e A NATIONAL SURVEY
Sophia Cashman, Evangelos Gkougkousis, Paula Allchorne, Bruce Turner,
James S.A. Green. Barts Health NHS Trust, London, UK.
Introduction: Current guidelines on the use of multiparametric MRI in
prostate cancer are limited. Its role indiagnosing and stagingprostate cancer
remains a subject of debate. We designed a questionnaire to assess thecurrent uptake of both staging MRI prior to treatment decision, and the use
of multiparametric MRI prior to initial prostate biopsy in target patients.
Methods: Questionnaires were handed out to healthcare professionals
involved with uro-oncology MDTs. Individuals at each of the urology
specialist multi-disciplinary team (SMDT) centres in England were also
contacted by email, with a link to the questionnaire.
Results: In total, 79 responses from 57 centres were received. Of these, 46
centres reported having a protocol which deﬁnes which patients have a
staging MRI prior to treatment decision. Nine centres report using multi-
parametric MRI prior to initial biopsy in target patient, which includes
centres using this as part of a research trial or service improvement
assessment.
Discussion: Our data suggests that the use of multiparametric MRI as an
imaging modality is limited. This is in keeping with the current limited
data on its value as a diagnostic tool. Further evidence is needed to assess
its role within the diagnostic pathway for prostate cancer.
1345: RADIATION EXPOSURE IN UROLOGICAL SURGERY: AN AUDIT OF
CLINICAL PRACTICE
Jennifer Martin, Paul Downey, Binu Thomas. Causeway Hospital, Coleraine,
Northern Ireland, UK.
Aim: Intraoperative radiology has led to an evolving awareness of the
potential risks of radiation exposure. The increased use of radiation within
urology necessitates further study and this audit evaluated its use in
comparison to guidelines produced by the IAEA (International Atomic
Energy Agency).
Methods: From January to September 2012, 176 patients were identiﬁed
from a retrospective review of theatre records, to have undergone one of
ﬁve types of urology surgery involving radiation exposure. Procedure type,
screening time and radiation dose area product were recorded, fromwhich
the effective radiation dose was calculated. Performance was reviewed and
compared against IAEA guidelines.
Results: All ﬁve procedures were found to have used lower levels of ra-
diation in comparison to the IAEA guidelines. Variations in radiation doses
between individual urologists were identiﬁed, with a particularly wide
effective radiation dose range of 0.8mSv to 1.9mSv found in the com-
monest procedure, ureteroscopy and laser lithotripsy.
Conclusions: Intra-operative radiation use at Causeway Hospital appears
to be well below the levels recommended by the IAEA. Measures to
continue to effectively treat urological disease whilst minimising patient
radiation exposure should be introduced.
1367: CAN TRANSPERINEAL SECTOR BIOPSY PREDICT FINAL PATHOL-
OGY MORE ACCURATELY THAN TRUS BIOPSY OR MRI?
David Eldred-Evans, Paul Sturch, Janette Kinsella, Prokar Dasgupta,
Rick Popert, Declan Cahill, Ben Challacombe. Guys and St. Thomas’
Hospital, London, UK.
Objectives: To compare the accuracy of TRUS biopsy, Transperineal sector
biopsy and multiparametric MRI (mp-MRI) at predicting ﬁnal pathology at
radical prostatectomy.
Methods: A retrospective diagnostic accuracy study of patients who all
had a mp-MRI, a TRUS biopsy and a transperineal sector biopsy followed
by a robot assisted radical prostatectomy (RARP) at a single institution
between January 2010 and December 2012. The ﬁnal pathology at radical
prostatectomy was compared across MRI, TRUS and TPSP.
Results: 104 consecutive patients were identiﬁed with a mean age 62
years (range 40-74) and a median PSA 7.9mg/L (range 0.8-40). The Gleason
score at radical prostatectomy was accurate in 71% transperineal sector
biopsies but only 27% TRUS biopsies. The Gleason score was upgraded in
77% TRUS biopsies compared to 16% transperineal sector biopsies.
There were 23 patients who had extracapsular extension (ECE) at radical
prostatectomy but only 25% were predicted by mp-MRI. The MRI did not
identify 12 patients staged at T3a and 4 patients staged at T3b.
Conclusions: Transperineal sector biopsy was the best predictor of ﬁnal
pathology. Neither TRUS biopsy nor MRI stage predicted ﬁnal pathology
reliably, particularly with regard to extracapsular extension, and this has
implications for the use of preoperative nomograms.
